BRCA1 negatively regulates IGF-1 expression through an estrogen-responsive element-like site

Cell Death and Disease

Volumn 3, Issue 6, 2012, Pages

  Kang, H J ^a   Yi, Y W ^a,b   Kim, H J ^a   Hong, Y B ^a,b   Seong, Y S ^b   Bae, I ^a,b  

^a GEORGETOWN UNIVERSITY   (United States)

^b Dankook University   (South Korea)

Author keywords

BRCA1; ERa; IGF 1; negative regulation; positive feedback activation

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ESTROGEN RECEPTOR ALPHA; MESSENGER RNA; NEUTRALIZING ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; BRCA1 PROTEIN, HUMAN; ESTROGEN;

ARTICLE; BREAST CANCER; CANCER CELL; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ESTROGEN RESPONSIVE ELEMENT; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROMOTER REGION; RECEPTOR BINDING; REPORTER GENE; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; BREAST TUMOR; DNA RESPONSIVE ELEMENT; FEMALE; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

BRCA1 PROTEIN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; ESTROGENS; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; PROMOTER REGIONS, GENETIC; RECEPTOR, IGF TYPE 1; RESPONSE ELEMENTS; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84863495707     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2012.78     Document Type: Article

References (40)

1. Ewing GP, Goff LW. The insulin-like growth factor signaling pathway as a target for treatment of colorectal carcinoma. Clin Colorectal Cancer 2010; 9: 219-223.
2. Fagan DH, Yee D. Crosstalk between IGF1R and estrogen receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia 2008; 13: 423-429.
3. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008; 8: 915-928.
4. Riedemann J, Macaulay VM. IGF1R signalling and its inhibition. Endocr Rel Cancer 2006; 13: S33-S43.
5. Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL et al. Phosphorylated insulinlike growth factor-I/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 2008; 68: 10238-10246.
6. Hewitt SC, Li Y, Li L, Korach KS. Estrogen-mediated regulation of Igf1 transcription and uterine growth involves direct binding of estrogen receptor a to estrogen-responsive elements. J Biol Chem 2010; 285: 2676-2685.
7. Shang Y, Brown M. Molecular determinants for the tissue specificity of SERMs. Science 2002; 295: 2465-2468.
8. Sasaki H, Hayakawa J, Terai Y, Kanemura M, Tanabe-Kimura A, Kamegai H et al. Difference between genomic actions of estrogen versus raloxifene in human ovarian cancer cell lines. Oncogene 2008; 27: 2737-2745.
9. Hudelist G, Wagner T, Rosner M, Fink-Retter A, Gschwantler-Kaulich D, Czerwenka K et al. Intratumoral IGF-I protein expression is selectively upregulated in breast cancer patients with BRCA1/2/ mutations. Endocr Rel Cancer 2007; 14: 1053-1062.
10. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66-71.
11. Thompson D, Easton D. Breast Cancer Linkage Consortium. Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol Biomarkers Prev 2002; 11: 329-336.
12. Wilson CA, Ramos L, Villaseñor MR, Anders KH, Press MF, Clarke K et al. Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Genet 1999; 21: 236-240.
13. Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000; 95: 564-569.
14. Rosen EM, Fan S, Pestell RG, Goldberg ID. The BRCA1 gene in breast cancer. J Cell Physiol 2003; 196: 19-41.
15. Mullan PB, Quinn JE, Harkin DP. The role of BRCA1 in transcriptional regulation and cell cycle control. Oncogene 2006; 25: 5854-5863.
16. Fan S, Wang J, Yuan R, Ma Y, Meng Q, Erdos MR et al. BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 1999; 284: 1354-1356.
17. Zheng L, Annab LA, Afshari CA, Lee WH, Boyer TG. BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. Proc Natl Acad Sci USA 2001; 98: 9587-9592.
18. Romagnolo D, Annab LA, Thompson TE, Risinger JI, Terry LA, Barrett JC et al. Estrogen upregulation of BRCA1 expression with no effect on localization. Mol Carcinogen 1998; 22: 102-109.
19. Umayahara Y, Kawamori R, Watada H, Imano E, Iwama N, Morishima T et al. Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer. J Biol Chem 1994; 269: 16433-16442.
20. Fan S, Ma YX, Wang C, Yuan RQ, Meng Q, Wang JA et al. Role of direct interaction in BRCA1 inhibition of estrogen receptor activity. Oncogene 2001; 20: 77-87.
21. Klotz DM, Hewitt SC, Ciana P, Raviscioni M, Lindzey JK, Foley J et al. Requirement of estrogen receptor-a in insulin-like growth factor-1 (IGF-1)-induced uterine responses and in vivo evidence for IGF-1/estrogen receptor cross-talk. J Biol Chem 2002; 277: 8531-8537.
22. Cascio S, Bartella V, Garofalo C, Russo A,Giordano A, Surmacz E. Insulin-like growth factor 1 differentially regulates estrogen receptor-dependent transcription at estrogen response element and AP-1 sites in breast cancer cells. J Biol Chem 2007; 282: 3498-3506.
23. Sarfstein R, Maor S, Reizner N, Abramovitch S, Werner H. Transcriptional regulation of the insulin-like growth factor-I receptor gene in breast cancer. Mol Cell Endocrinol 2006; 252: 241-246.
24. Shukla V, Coumoul X, Cao L, Wang RH, Xiao C, Xu X et al. Absence of the full-length breast cancer-associated gene-1 leads to increased expression of insulin-like growth factor signaling axis members. Cancer Res 2006; 66: 7151-7157.
25. Schayek H, Haugk K, Sun S, True LD, Plymate SR, Werner H. Tumor suppressor BRCA1 is expressed in prostate cancer and control insulin-like growth factor I receptor (IGF-IR) gene transcription in an androgen receptor-dependent manner. Clin Cancer Res 2009; 15: 1558-1565.
26. Levin ER. Membrane oestrogen receptor a signaling to cell functions. J Physiol 2009; 587: 5019-5023.
27. Burga LN, Tung NM, Troyan SL, Bostina M, Konstantinopoulos PA, Fountzilas H et al. Altered proliferation and differentiation properties of primary mammary epithelial cells from BRCA1 mutation carriers. Cancer Res 2009; 69: 273-1278.
28. Tung N, Wang Y, Collins LC, Kaplan J, Li H, Gelman R et al. Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features. Breast Cancer Res 2010; 12: R12.
29. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336: 1401-1408.
30. Laitman Y, Borsthein RT, Stoppa-Lyonnet D, Dagan E, Castera L, Goislard M et al. Germline mutations in BRCA1 and BRCA2 genes in ethnically diverse high risk families in Israel. Breast Cancer Res Treat 2011; 127: 489-495.
31. Fan S, Ma YX, Wang C, Yuan RQ, Meng Q, Wang JA et al. p300 modulates the BRCA1 inhibition of estrogen receptor activity. Cancer Res 2002; 62: 141-151.
32. Wang C, Fan S, Li Z, Fu M, Rao M, Ma Y et al. Cyclin D1 antagonizes BRCA1 repression of estrogen receptor alpha activity. Cancer Res 2005; 65: 6557-6567.
33. Yu X, Wu LC, Bowcock AM, Aronheim A, Baer R. The C-terminal (BRCT) domains of BRCA1 interact in vito with CtIP, a protein implicated in the CtBP pathway of transcriptional repression. J Biol Chem 1998; 273: 25388-25392.
34. Yarden RI, Brody LC. BRCA1 interacts with components of the histone deacetylase complex. Proc Natl Acad Sci USA 1999; 96: 4983-4988.
35. Chang S, Wang RH, Akagi K, Kim KA, Martin BK, Cavallone L et al. Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155. Nat Med 2011; 17: 1275-1282.
36. Hu YF, Li R. Jun B potentiates function of BRCA1 activation domain 1 (AD1) through a coiled-coil-mediated interaction. Genes Dev 2002; 16: 1509-1517.
37. Shakya R, Reid LJ, Reczek CR, Cole F, Egli D, Lin CS et al. BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity. Science 2011; 334: 525-528.
38. Kang HJ, Kim HJ, Kim SK, Barouki R, Cho CH, Khanna KK et al. BRCA1 modulates xenobiotic stress-inducible gene expression by interacting with ARNT in human breast cancer cells. J Biol Chem 2006; 281: 14654-14662.
39. Kang HJ, Kim HJ, Rih JK, Mattson TL, Kim KW, Cho CH et al. BRCA1 plays a role in the hypoxic response by regulating HIF-1a stability and by modulating vascular endothelial growth factor expression. J Biol Chem 2006; 281: 13047-13056.
40. Jones LP, Sampson A, Kang HJ, Kim HJ, Yi YW, Kwon SY et al. Loss of BRCA1 leads to an increased sensitivity to Bisphenol A. Toxicol Lett 2010; 199: 261-268.